Israel’s Trobix Bio is using CRISPR, phage, and synthetic biology technologies to develop precision microbiome oncology therapeutics. TBX101 counters anti-biotic resistance; TBX201 reduces chemotherapy side-effects; TBX301 tackles gut inflammation. https://www.trobix.bio/ https://www.youtube.com/watch?v=h1MsWkhBAyM

Israel’s PainReform has just completed a Phase 3 human trial of its PRF-110 post-operative pain relief. The oil-based, viscous, clear solution is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. https://painreform.com/releases/painreform-announces-positive-safety-data-in-first-part-of-phase-3-clinical-trialof-prf-110-in-patients-undergoing-bunionectomy-surgery/

The 15-min BV test from Israel’s MeMed (see here previously) accurately diagnosed over 90% of bacterial versus viral infections at Israel’s Schneider Children’s Medical Center, reducing Emergency Department physician error. The study tested 287 children from 3 months to 18 … Continue reading →

The US FDA has approved UZEDY (risperidone), developed for the treatment of schizophrenia by Israel’s Teva and France’s Medincell. In a Phase 3 human clinical trial, UZEDY demonstrated up to 80% reduction in risk of schizophrenia relapse versus a placebo. … Continue reading →

Israel’s Nanox (see here previously) has received US FDA approval for its light-weight imaging system for clinics and hospitals. The Nanox.ARC can employ up to five separate X-ray-emitting tubes at once for a 3D image. The FDA approved Nanox’s single-source … Continue reading →

Researchers led by Professor Ido Amit of Israel’s Weizmann Institute, have discovered that the kidney is the source of the hormone EPO (erythropoietin), which turns cells in the bone marrow into oxygen-carrying red blood cells. Increasing EPO in kidney disease … Continue reading →